Showing Latest Articles
Identification of a novel biomarker candidate, a 4.8-kDa peptide fragment from a neurosecretory protein VGF precursor, by proteomic analysis of cerebrospinal fluid from children with acute encephalopathy using SELDI-TOF-MS Full Text
BMC Neurology, 08/19/2011
Asano T et al. – Expression of VGF4.8 has been reported to be decreased in pathologically degenerative changes such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and encephalopathy. Thus, the VGF4.8 peptide might be a novel marker for degenerative brain conditions.
Methods- For detection of biomarkers, CSF samples were obtained from 13 children with acute encephalopathy and 42 children with febrile seizure.
- Mass spectral data were generated by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) technology, which is currently applied in many fields of biological and medical sciences.
- Diagnosis was made by at least two pediatric neurologists based on the clinical findings and routine examinations.
- All specimens were collected for diagnostic tests and the remaining portion of the specimens were used for the SELDI-TOF MS investigations.
- In experiment 1, CSF from patients with febrile seizures (n=28), patients with encephalopathy (n=8) (including influenza encephalopathy (n=3), encephalopathy due to rotavirus (n=1), human herpes virus 6 (n=1)) and patients with fever without neurological involvement such as convulsions (n=11) were used for the SELDI analysis.
- In experiment 2, SELDI analysis was performed on CSF from a second set of febrile seizure patients (n=14) and encephalopathy patients (n=5).
- This study founds that the peak with an m/z of 4810 contributed the most to the separation of the two groups.
- After purification and identification of the 4.8-kDa protein, a 4.8-kDa proteolytic peptide fragment from the neurosecretory protein VGF precursor (VGF4.8) was identified as a novel biomarker for encephalopathy.
